MIM
BHVN

MetLife Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

MetLife Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,319
Closed -$5.04M – 2888
2022
Q3 		$5.04M Buy
33,319
+985
+3% +$146K 0.04% 402
2022
Q2 		$4.71M Buy
32,334
+2,495
+8% +$319K 0.04% 454
2022
Q1 		$3.54M Buy
29,839
+10,558
+55% +$1.32M 0.02% 732
2021
Q4 		$2.66M Hold
19,281
– – 0.02% 737
2021
Q3 		$2.68M Hold
19,281
– – 0.02% 710
2021
Q2 		$1.87M Buy
19,281
+1,065
+6% +$86.4K 0.02% 905
2021
Q1 		$1.25M Sell
18,216
-1,475
-7% -$119K 0.01% 1047
2020
Q4 		$1.69M Sell
19,691
-1,125
-5% -$95.3K 0.02% 908
2020
Q3 		$1.35M Hold
20,816
– – 0.01% 895
2020
Q2 		$1.52M Buy
20,816
+2,407
+13% +$128K 0.02% 842
2020
Q1 		$626K Buy
18,409
+1,060
+6% +$48.5K 0.01% 1096
2019
Q4 		$944K Hold
17,349
– – 0.01% 1128
2019
Q3 		$724K Buy
17,349
+3,381
+24% +$143K 0.01% 1221
2019
Q2 		$612K Hold
13,968
– – 0.01% 1367
2019
Q1 		$719K Buy
13,968
+1,801
+15% +$77.8K 0.01% 1233
2018
Q4 		$450K Hold
12,167
– – 0.01% 1431
2018
Q3 		$457K Buy
+12,167
New +$448K ﹤0.01% 1592

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

MetLife Investment Management's BHVN Position: Q4 2022 in Review

MetLife Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 33,319 shares — an estimated $5.04M sold.

MetLife Investment Management first reported a position in BHVN in Q3 2018 and held it in 17 quarters. The position peaked at $5.04M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • MetLife Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • MetLife Investment Management sold 33,319 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $5.04M.
  • MetLife Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 17 quarters.
  • MetLife Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.04M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.